Sort   by:  
 Page size 
UnknownIbudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial.
Not available
S-EPMC8102622 | biostudies-literature
UnknownThe relationship between objective parameters of sleep and measures of fatigue, depression, and cognition in multiple sclerosis.
Not available
S-EPMC5433423 | biostudies-literature
UnknownUsing modified Ashworth scale for assessing multiple sclerosis-associated spasticity: a high time for a paradigm shift.
Not available
S-EPMC9940219 | biostudies-literature
UnknownLymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing-Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study.
Not available
S-EPMC11263526 | biostudies-literature
UnknownDe-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who Switched from Ocrelizumab to Diroximel Fumarate.
Not available
S-EPMC11263251 | biostudies-literature
UnknownComputerized neuropsychological assessment devices in multiple sclerosis: A systematic review.
Not available
S-EPMC6875828 | biostudies-literature
UnknownEffect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis.
Not available
S-EPMC7227148 | biostudies-literature
UnknownEfficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study.
Not available
S-EPMC8870078 | biostudies-literature
UnknownDiroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Not available
S-EPMC7604551 | biostudies-literature
UnknownRare variants and HLA haplotypes associated in patients with neuromyelitis optica spectrum disorders.
Not available
S-EPMC9578444 | biostudies-literature
Sort   by:  
 Page size